Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Change in Receivables (2023 - 2025)

Bioregenx (BRGX) has 3 years of Change in Receivables data on record, last reported at $41495.0 in Q3 2025.

  • For Q3 2025, Change in Receivables rose 388.23% year-over-year to $41495.0; the TTM value through Sep 2025 reached $43168.0, up 169.01%, while the annual FY2024 figure was -$89589.0, 523.75% down from the prior year.
  • Change in Receivables reached $41495.0 in Q3 2025 per BRGX's latest filing, up from $9960.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $41495.0 in Q3 2025 and bottomed at -$93406.0 in Q1 2024.
  • Average Change in Receivables over 3 years is -$1893.5, with a median of $1442.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: plummeted 482.15% in 2024, then soared 4393.1% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $22584.0 in 2023, then tumbled by 119.7% to -$4450.0 in 2024, then surged by 1032.47% to $41495.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $41495.0 in Q3 2025, $9960.0 in Q2 2025, and -$3837.0 in Q1 2025.